The estimated Net Worth of Venture Capital Vi, L.P.Ver... is at least $17 Milhão dollars as of 27 November 2020. Venture Ver owns over 10,393 units of Black Diamond Therapeutics Inc stock worth over $5,358,227 and over the last 5 years Venture sold BDTX stock worth over $11,667,763.
Venture has made over 15 trades of the Black Diamond Therapeutics Inc stock since 2020, according to the Form 4 filled with the SEC. Most recently Venture sold 10,393 units of BDTX stock worth $344,528 on 27 November 2020.
The largest trade Venture's ever made was buying 894,736 units of Black Diamond Therapeutics Inc stock on 3 February 2020 worth over $16,999,984. On average, Venture trades about 59,273 units every 14 days since 2020. As of 27 November 2020 Venture still owns at least 874,099 units of Black Diamond Therapeutics Inc stock.
You can see the complete history of Venture Ver stock trades at the bottom of the page.
Over the last 5 years, insiders at Black Diamond Therapeutics Inc have traded over $26,407,257 worth of Black Diamond Therapeutics Inc stock and bought 10,796,678 units worth $105,501,601 . The most active insiders traders include Ali Behbahani, Rajeev M. Shah, eCapital Management, L.P.Ra .... On average, Black Diamond Therapeutics Inc executives and independent directors trade stock every 21 days with the average trade being worth of $899,443. The most recent stock trade was executed by Venture Capital Vi, L.P.Ver... on 28 August 2024, trading 221,600 units of BDTX stock currently worth $1,400,512.
black diamond therapeutics, inc., a precision oncology medicine company, discovers and develops small molecule, tumor-agnostic therapies. its lead product candidate is bdtx-189, an inhibitor of non-canonical and oncogenic mutations of erbb kinases epidermal growth factor receptor (egfr) and tyrosine-protein kinase. the company is also developing allosteric-egfr mutation inhibitors; and various early stage pipeline programs targeting allosteric mutations in kinases related to cancer and/or rare genetic diseases. the company was formerly known as aset therapeutics, inc. and changed its name to black diamond therapeutics, inc. in january 2018. black diamond therapeutics, inc. was founded in 2014 and is headquartered in cambridge, massachusetts.
Black Diamond Therapeutics Inc executives and other stock owners filed with the SEC include: